Diacylglycerol Signaling

426 A. Basu
Higgins, C. F. (1993). The multidrug resistance P-glycoprotein. Current Opinion in Cell Biology,
5, 684–687.
Hirata, J., Kikuchi, Y., Kita, T., Imaizumi, E., Tode, T., Ishii, K., et al. (1993). Modulation of
sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by
12-O-tetradecanoylphorbol-13-acetate and D, L-buthionine-S, R-sulphoximine. International
Journal of Cancer, 55, 521–527.
Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F., et al. (1988). Enhancement
of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by
inhibitors of protein kinase C. International Journal of Cancer, 42, 382–388.
Huang, J., Mohanty, S., & Basu, A. (2004). Cisplatin resistance is associated with deregulation in
protein kinase C-delta. Biochemical and Biophysical Research Communications, 316,
1002–1008.
Ido, M., Asao, T., Sakurai, M., Inagaki, M., Saito, M., & Hidaka, H. (1986). An inhibitor of
protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine(H-7) inhibits TPA-induced
reduction of vincristine uptake from P388 murine leukemic cell. Leukemia Research, 10,
1063–1069.
Ido, M., Sato, K., Sakurai, M., Inagaki, M., Saitoh, M., Watanabe, M., et al. (1987). Decreased
phorbol ester receptor and protein kinase C in P388 murine leukemic cells resistant to etoposide.
Cancer Research, 47, 3460–3463.
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin
mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National
Academy of Sciences of the United States of America, 99, 14298–14302.
Isonishi, S., Andrews, P. A., & Howell, S. B. (1990). Increased sensitivity to cis-diamm
inedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with
12-O-tetradecanoylphorbol 13-acetate. The Journal of Biological Chemistry, 265,
3623–3627.
Isonishi, S., Hom, D. K., Eastman, A., & Howell, S. B. (1994). Enhancement of sensitivity to
platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian
carcinoma cell line. British Journal of Cancer, 69, 217–221.
Jiffar, T., Kurinna, S., Suck, G., Carlson-Bremer, D., Ricciardi, M. R., Konopleva, M., et al.
(2004). PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects
on Bcl2 phosphorylation. Leukemia, 18, 505–512.
Kameyama, N., Arisawa, S., Ueyama, J., Kagota, S., Shinozuka, K., Hattori, A., et al. (2008).
Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB
p65 in the livers of rats with streptozotocin-induced diabetes. Biochimica et Biophysica Acta,
1782, 355–360.
Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews.
Cancer, 7, 573–584.
Kerr, J. F., Winterford, C. M., & Harmon, B. V. (1994). Apoptosis. Its significance in cancer and
cancer therapy. Cancer, 73, 2013–2026.
Killion, J. J., Beltran, P., O’Brian, C. A., Yoon, S. S., Fan, D., Wilson, M. R., et al. (1995). The antitumor
activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration
of a synthetic staurosporine analogue, CGP 41251. Oncology Research, 7, 453–459.
Kim, E. H., Lee, H. J., Lee, D. H., Bae, S., Soh, J. W., Jeoung, D., et al. (2007). Inhibition of heat
shock protein 27-mediated resistance to DNA damaging agents by a novel PKC delta-V5
heptapeptide. Cancer Research, 67, 6333–6341.
Kurinna, S., Konopleva, M., Palla, S. L., Chen, W., Kornblau, S., Contractor, R., et al. (2006). Bcl2
phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia,
20, 1316–1319.
Lee, S. A., Karaszkiewicz, J. W., & Anderson, W. B. (1992). Elevated level of nuclear protein
kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Research, 52,
3750–3759.
Lu, Y., Jamieson, L., Brasier, A. R., & Fields, A. P. (2001). NF-kappaB/RelA transactivation is
required for atypical protein kinase C iota-mediated cell survival. Oncogene, 20, 4777–4792.